AN
47
3
HRB
56
2
AXP
64
4
JBHT
63
3
JNPR
59
3
AIZ
54
7
BLK
69
3
AMAT
46
6
AVGO
32
7
HCA
53
3
MKC
56
3
CHD
45
3
WMB
63
3
OKE
68
4
GIS
29
3
WY
53
2
MPC
31
5
XYL
35
4
FTI
66
2
LB
45
15
AN
47
3
HRB
56
2
AXP
64
4
JBHT
63
3
JNPR
59
3
AIZ
54
7
BLK
69
3
AMAT
46
6
AVGO
32
7
HCA
53
3
MKC
56
3
CHD
45
3
WMB
63
3
OKE
68
4
GIS
29
3
WY
53
2
MPC
31
5
XYL
35
4
FTI
66
2
LB
45
15
Financhill
Back

Regeneron Pharmaceuticals 10K Form

Sell
37

REGN
Regeneron Pharmaceuticals

Last Price:
829.32
Seasonality Move:
11.8%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-11-02 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-08-03 10Q REGN/Regeneron Pharmaceuticals Quarterly
2023-05-04 10Q REGN/Regeneron Pharmaceuticals Quarterly
2022-11-03 10Q REGN/Regeneron Pharmaceuticals Quarterly
2022-08-03 10Q REGN/Regeneron Pharmaceuticals Quarterly

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales: $13.12B
Cash Flow: $1.05B
Price / Cash Flow: 28.76
Annual Sales: $266.32
Price / Book: 3.11

Profitability

EPS (TTM): 40.41000
Net Income (TTM): $4.65B
Gross Margin: $11.3B
Return on Equity: 17.19%
Return on Assets: 13.44%

Regeneron Pharmaceuticals Earnings Forecast

Key Regeneron Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 34 years for REGN is 86.16%.
  • The Selling, General & Administrative Expenses for REGN have been equal to 20.06% of Gross Profit Margin.
  • The Research & Development expenses have been 33.84% of Revenue.
  • The Interest Expense is 1.85% of Operating Income.
  • The Net Earning history of REGN is 30.14% of Total Revenues.
  • Per Share Earnings over the last 34 years have been positive in 18 years.

Regeneron Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Biotechnology
Sector: Health Care
Current Symbol: REGN
CUSIP: 75886F
Website: regeneron.com

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 5.28
Quick Ratio: 4.34

Price-to-Earnings

Trailing P/E Ratio: 23.85
Forward P/E Ratio: 18.21

REGN Technical Analysis vs Fundamental Analysis

Sell
37
Regeneron Pharmaceuticals (REGN) is a Sell

Is Regeneron Pharmaceuticals a Buy or a Sell?